WKN: A2AN1Z ISIN: SE0000767188
aktueller Kurs:
0,89 EUR
0,05 EUR
Veränderung in %:
5,70 %
weitere Analysen einblenden

Alligator Bioscience receives patent approval for the drug candidate ATOR-1015

Mittwoch, 16.09.20 08:45
Kursticker auf einer digitalen Anzeige.
Bildquelle: pixabay

PR Newswire

LUND, Sweden, Sept. 16, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,774,150 which covers compositions of matter directed to Alligator's bispecific drug candidate ATOR-1015. The granted patent's earliest expiry year is 2036.

"ATOR-1015 constitutes a new concept, a tumor-localizing bispecific CTLA-4 antibody. Our invention addresses one of the key challenges within immuno-oncology, i.e. the narrow therapeutic window of CTLA-4 drugs. This is now protected by a granted US patent," commented Per Norlén, CEO at Alligator Bioscience.

ATOR-1015 is developed for the treatment of metastatic cancer. Promising safety data from the ongoing ATOR-1015 Phase I clinical study was presented at ASCO in June 2020. The Phase I dose escalation study is planned to be completed during the fourth quarter 2020 and the subsequent Phase Ib efficacy study in malignant melanoma is due to start in 2021.

For further information, please contact:

Cecilia Hofvander, Director Investor Relations & Communications

Phone +46 46 540 82 06


The information was submitted for publication, through the agency of the contact person set out above, at 08:30 a.m. CEST on September 16, 2020.

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's pipeline includes five lead clinical and preclinical drug candidates: Mitazalimab, ATOR-1015, ATOR-1017, ALG.APV-527 (co-developed with Aptevo Therapeutics Inc.) and AC101 (in clinical development by Shanghai Henlius Biotech Inc.). Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden. For more information, please visit

This information was brought to you by Cision,c3194695

The following files are available for download: Bioscience receives patent approval for the drug candidate ATOR-1015

Quelle: PR Newswire

Hier geht's zur Aktien-Startseite

News und Analysen

Alligator Bioscience launches a new immuno-oncology concept

PR NewswireLUND, Sweden, Sept. 24, 2020LUND, Sweden, Sept. 24, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the company launches a new concept ...weiterlesen

Seite: 1 | 2 | 3 | 4 | ►


Im Fokus

Aktueller Chart
  • +370% Kursgewinn seit Jahresstart!
  • Explodiert die Tesla-Aktie wieder?
  • Jetzt gratis Tesla-Report downloaden!


Value oder Growth? Eine Frage so alt wie die Börse

Value oder Growth? Eine Frage so alt wie die Börse
Die Frage, ob es sinnvoller ist, auf Value- oder auf Growth-Titel zu setzen, ist beinahe so alt wie die Börse selbst. Dabei sind mit der Bezeichnung „Value“ bewährte Unternehmen gemeint, deren Buchwert idealerweise aktuell möglichst niedrig bewertet wird.
© 1994-2020 by - Quelle für Kurse und Daten: ARIVA.DE AG - übernimmt keine Gewähr